Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...
Brent Saunders returned to Bausch + Lomb in 2023 to help address unmet needs in eye care, focusing on innovation and ...
The FDA has approved Flow Neuroscience's at-home brain stimulation device to treat depression, offering an alternative to ...
Thermo Fisher Scientific’s Accelerator Drug Development is a suite of integrated services combining CDMO and CRO capabilities to streamline the drug development journey, from early-stage research to ...
Biphenomycins, natural products derived from bacteria, show excellent antimicrobial activity, but have long remained out of ...
The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...
LNK01006 recently received IND clearance from the FDA to initiate first-in-human studies in the US. Formation Bio plans to initiate a Phase 1 study in the first half of 2026, reflecting the company's ...
Objectives Functional foods have demonstrated potential in preventing gastrointestinal and musculoskeletal (osteo-related) ...
At a time when investors are questioning the sustainability of pharmaceutical business models, reliable execution has become ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback